Edgar D. Charles MD, MS

Edgar Charles leads Bristol Myers Squibb’s clinical fibrosis development program. Here, he is responsible for the global clinical development and development strategy for multiple liver fibrosis assets, setting therapeutic strategies, defining clinical plans, and designing Phase 0-3 trials. Prior to joining Bristol Myers Squibb, Edgar spent three years at Merck Research Laboratories where he led emerging markets infectious disease strategy and served as a global clinical lead for hepatitis C therapies.

Before joining the industry, Edgar spent 10 years at Rockefeller University, where as an assistant professor he led a basic science and translational research program to understand the mechanisms of virus-induced autoimmunity in humans. Edgar’s research identified and functionally characterized a novel B cell subset responsible for human autoimmunity. During his time at Rockefeller University, he conducted post-doctoral virology and immunology research and served as a member or chairman of several hospital committees. He also practiced medicine at Manhattan Veterans Administration Hospital and Bellevue Hospital.

Edgar received his MD, from the University of Alabama School of Medicine, and later his MSc in the clinical and translational investigation at Rockefeller University. He completed his residency in internal medicine and fellowship in infectious diseases at New York University School of Medicine. Edgar has published and presented in the fields of virology, immunology, infectious diseases, autoimmunity, and fibrosis.